Despite the success of CAR T cell-based immunotherapies, patients with non-Hodgkin lymphoma (NHL) face a high risk of recurrence. Here, the authors report clinical outcomes of a phaseI/II study on refractory NHL patients treated with anti-CD19-anti-CD20 CAR T cell product epigenetically reprogrammed with decitabine and CAR T cel properties. In addition, they investigate the persistence and fate of the CAR T cell product, indicating the acquisition of memory-like features, maintained cytotoxicity and reduced exhaustion signature.
- Chunmeng Wang
- Yelei Guo
- Weidong Han